Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827728 | 0.82 | ACHE (0.53) | LMNATSHRALOX12ACHENQO2 | |
| Water SCHEMBL27955558 | 0.80 | ACHE (0.50) | LMNATSHRALOX12ACHENQO2 | |
| SCHEMBL26417080 | 0.79 | BBOX1 (0.39) | LMNATSHRALOX12ACHEALDH1A1 | |
| Toluene SCHEMBL3837745 | 0.76 | — | — | |
| SCHEMBL339826 | 0.76 | BBOX1 (0.41) | LMNATSHRALOX12ACHEALDH1A1 | |
| Benzene SCHEMBL27586265 | 0.73 | BBOX1 (0.39) | LMNATSHRALOX12ACHEALDH1A1 | |
| Bromide SCHEMBL9081012 | 0.73 | BBOX1 (0.39) | LMNATSHRALOX12ACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL30702244 | 0.73 | BBOX1 (0.39) | LMNATSHRALOX12ACHEALDH1A1 | |
| SCHEMBL338835 | 0.70 | ACHE (0.57) | LMNATSHRALOX12ACHENQO2 | |
| SCHEMBL14599316 | 0.67 | CA12 (0.53) | LMNAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | LMNA 3778/4885TSHR 195/4885ALOX12 2831/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | LMNA 3778/4885TSHR 195/4885ALOX12 2831/4885 |
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | LMNA 3778/4885TSHR 195/4885ALOX12 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.